[INTERNATIONAL COOPERATION IN PEDIATRIC RHEUMATOLOGY: THE SHARE PROJECT]

Yosef Uziel1

  • 1Pediatric Rheumatology Unit, Pediatric Department, Meir Medical Center Kfar Saba, affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Harefuah
|August 9, 2017
PubMed

Insights

The SHARE initiative by the European Society of Pediatric Rheumatology enhanced pediatric rheumatology care through comprehensive surveys and resource mapping. This project established best practices for diagnosis, treatment, and international research collaboration in pediatric rheumatic diseases.

Area of Science:

  • Pediatric Rheumatology
  • Clinical Care Improvement
  • International Healthcare Collaboration

Background:

  • The SHARE initiative, launched by the European Society of Pediatric Rheumatology, aimed to enhance clinical care in pediatric rheumatology.
  • It involved extensive surveys and mapping of pediatric rheumatology centers across countries to assess resources and treatment quality.

Purpose of the Study:

  • To improve the diagnosis and treatment of rheumatic diseases in children.
  • To establish optimal clinical approaches and care standards.
  • To foster international research and collaboration in pediatric rheumatology.

Main Methods:

  • Conducting comprehensive surveys of pediatric rheumatology centers, including staff, treatments, and quality.
  • Mapping resources and identifying best practices for pediatric rheumatic disease management.
  • Developing position papers with evidence-based recommendations and guidelines.

Main Results:

  • Identification of optimal clinical approaches and care standards for pediatric rheumatic diseases.
  • Establishment of recommendations for enhancing international research, including genetic studies and sample sharing.
  • Increased availability of patient information and development of educational programs for healthcare professionals.

Conclusions:

  • The SHARE initiative successfully improved pediatric rheumatology care through standardized approaches and resource optimization.
  • It laid the groundwork for enhanced international research collaboration and knowledge sharing.
  • The project promoted higher and more uniform academic standards in pediatric rheumatology globally.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
359
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
610
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
375
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
408
Acute Kidney Injury V: Interprofessional Care01:20

Acute Kidney Injury V: Interprofessional Care

Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
380
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
752